A carregar...
SUN-340 Prolactinoma Response to Bevacizumab Is Influenced by Tumor Progression Stage at the Beginning of Treatment
Anti-VEGF therapy is being implemented as second line drug for aggressive pituitary adenomas that do not respond to conventional treatments. Although it is approved for treatment of several cancers, many of them acquire resistance. In the present work, we evaluated Bevacizumab (BVZ) effect in an in...
Na minha lista:
| Publicado no: | J Endocr Soc |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Endocrine Society
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6553318/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-340 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|